
CREATE Medicines Targets Autoimmune Diseases with In Vivo CAR-T Therapy
The Australian Human Research Ethics Committee has cleared CREATE Medicines to launch a Phase 1/2 clinical trial for CRT-402, marking the company’s first push into autoimmune treatments. The study will evaluate the therapy in patients suffering from systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies.
)

























